（编辑 任世碧） 证券日报网讯 1月23日，华仁药业在互动平台回答投资者提问时表示，公司积极布局饮料、化妆品、健 康饮品等大健康产品线，饮料业务包括电解质补充液、纯净水、大桶水、葡萄糖补水液、固体饮料等产 品，化妆品业务方面名济堂化妆品是子公司湖北华仁同济与华中科技大学同济医学院附属同济医院合作 的"华仁同济联合实验室"研制，主打医学科学护肤，目前主要产品有胶原蛋白睡眠面膜、小分子胶原蛋 白水、维生素E水润霜、极光晚安精华液、维生素E乳、防晒乳等，健康饮品方面由子公司湖北华仁同 济开发并由"华仁同济联合实验室"技术支持的"华仁同济燕窝胶原三肽饮"已上市，进一步丰富了公司的 大健康产品线，该系列产品目前销售收入占比还较小，后续公司将加强品牌建设和渠道建设，持续推进 大健康产品线上、线下销售渠道的开发与推广。 ...

Financial Performance - The net profit attributable to shareholders for 2024 was a loss of ¥1,368,478,968.49 [3] - In Q1 2025, the net profit attributable to shareholders was ¥16,028,449.64 [3] - The overall revenue for the pharmaceutical manufacturing industry in 2024 was ¥25,298.50 billion, remaining stable compared to 2023, while the total profit decreased by 1.1% [13] Market Strategy - The company aims to maintain a high market share in peritoneal dialysis solutions by actively participating in national and local procurement initiatives [1] - The company plans to enhance customer management and service levels, leveraging the advantages of winning procurement bids to deepen sales channels [2] - The target for the medical device and packaging sector in 2025 is to achieve full coverage of key drug-related medical devices and a self-sufficiency rate of over 90% for packaging [4] Product Development - The company is expanding its health product lines, including beverages, cosmetics, and health drinks, with a focus on brand and channel development [5][6] - Six new raw materials and formulations were approved in 2024, contributing to the expectation of revenue growth [6] - The company has 20 products and 23 specifications that have passed or are deemed to have passed consistency evaluations, enhancing competitiveness in key therapeutic areas [7] Sales Model - In 2024, direct sales accounted for 39.47% and distribution sales accounted for 60.53% of total sales [7] Challenges and Future Outlook - The significant decline in Q1 2025 performance was attributed to the implementation of national drug price governance and participation in procurement, leading to lower sales prices [9][11] - The company is optimistic about future profitability, focusing on core business areas and improving product structure and management efficiency [11] - Despite current challenges, the long-term growth logic of the pharmaceutical industry remains intact, driven by factors such as aging population and increased health awareness [13] Social Responsibility - The company emphasizes environmental protection and sustainable development, having successfully passed re-certification for environmental and occupational health safety management systems in 2024 [8]